Overview of recent progress in protein-expression technologies for small-molecule screening

Journal of Biomolecular Screening

Volumn 19, Issue 7, 2014, Pages 1000-1013

  Cuozzo, John W ^a   Soutter, Holly H ^a  

^a X Chem Incorporated   (United States)

Author keywords

drug targets; Protein expression; review; screening; small molecule

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; CODON; HYBRID PROTEIN; RECOMBINANT PROTEIN;

BACULOVIRUS EXPRESSION SYSTEM; CODON; DRUG SCREENING; GENE SYNTHESIS; HUMAN; LIPID BILAYER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; ANIMAL; CHEMISTRY; DRUG DESIGN; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HEK293 CELL LINE; INSECT; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PHOSPHORYLATION; PROCEDURES; PROTEIN DATABASE; PROTEOMICS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CODON; DATABASES, PROTEIN; DRUG DESIGN; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INSECTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84904686062     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114520975     Document Type: Review

References (132)

1. Pereira D., Williams J.. Origin and Evolution of High Throughput Screening. Br. J. Pharmacol. 2007 ; 152 (1). 53-61
2. Kodadek T.. Rethinking Screening. Nat. Chem. Biol. 2010 ; 6 (3). 162-165
3. Bamborough P.. System-Based Drug Discovery within the Human Kinome. Expert Opin. Drug Discov. 2012 ; 7 (11). 1053-1070
4. Engel K., Vuissoz J.-M., Eggimann S., et al. Bacterial Expression of Mutant Argininosuccinate Lyase Reveals Imperfect Correlation of in-Vitro Enzyme Activity with Clinical Phenotype in Argininosuccinic Aciduria. J. Inher. Metab. Dis. 2012 ; 35 (1). 133-140
5. Zhuang Y., Durrani S., Hodges B., et al. Expression of Recombinant Ara h 6 in Pichia pastoris but Not in Escherichia coli Preserves Allergic Effector Function and Allows Assessment of Specific Mutations. Molec. Nutr. Food Res. 2012 ; 56 (6). 986-995
6. Clark M. A., Acharya R. A., Arico-Muendel C. C., et al. Design, Synthesis and Selection of DNA-Encoded Small-Molecule Libraries. Nat. Chem. Biol. 2009 ; 5 (9). 647-654
7. Zhu Z., Cuozzo J.. Review Article: High-Throughput Affinity-Based Technologies for Small-Molecule Drug Discovery. J. Biomol. Screen. 2009 ; 14 (10). 1157-1164
8. Nettleship J., Assenberg R., Diprose J., et al. Recent Advances in the Production of Proteins in Insect and Mammalian Cells for Structural Biology. J. Struct. Biol. 2010 ; 172 (1). 55-65
9. Rask-Andersen M., Almén M., Schiöth H.. Trends in the Exploitation of Novel Drug Targets. Nature Rev. Drug Disc. 2011 ; 10 (8). 579-590
10. Dixon S., Stockwell B.. Identifying Druggable Disease-Modifying Gene Products. Curr. Opin. Chem. Biol. 2009 ; 13 (5-6). 549-555
11. Overington J., Al-Lazikani B., Hopkins A.. How Many Drug Targets Are There?. Nature Rev. Drug Disc. 2006 ; 5 (12). 993-996
12. Clark M. A.. Selecting Chemicals: The Emerging Utility of DNA-Encoded Libraries. Curr. Opin. Chem. Biol. 2010 ; 14 (3). 396-403
13. Verdine G., Walensky L.. The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members. Clin. Cancer Res. 2007 ; 13 (24). 7264-7270
14. Crews C.. Targeting the Undruggable Proteome: The Small Molecules of My Dreams. Chem. Biol. 2010 ; 17 (6). 551-555
15. Kufareva I., Ilatovskiy A., Abagyan R.. Pocketome: An Encyclopedia of Small-Molecule Binding Sites in 4D. Nucl. Acids Res. 2012 ; 40 (Database issue). 40
16. Biondi R., Kieloch A., Currie R., et al. The PIF-Binding Pocket in PDK1 Is Essential for Activation of S6K and SGK, but Not PKB. EMBO J. 2001 ; 20 (16). 4380-4390
17. Bobkova E., Weber M., Xu Z., et al. Discovery of PDK1 Kinase Inhibitors with a Novel Mechanism of Action by Ultrahigh Throughput Screening. J. Biol. Chem. 2010 ; 285 (24). 18838-18846
18. Magesh S., Chen Y., Hu L.. Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents. Med. Res. Rev. 2012 ; 32 (4). 687-726
19. Kim T.-H., Hur E.-G., Kang S.-J., et al. NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1. Cancer Res. 2011 ; 71 (6). 2260-2275
20. Steel R., Cowan J., Payerne E., et al. Anti-Inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction. ACS Med. Chem. Lett. 2012 ; 3 (5). 407-410
21. Choo Y., Hagen T.. Mechanism of Cullin3 E3 Ubiquitin Ligase Dimerization. PloS One. 2012 ; 7 (7). e41350
22. Li X., Zhang D., Hannink M., et al. Crystal Structure of the Kelch Domain of Human Keap1. J. Biol. Chem. 2004 ; 279 (52). 54750-54758
23. Hu L., Magesh S., Chen L., et al. Discovery of a Small-Molecule Inhibitor and Cellular Probe of Keap1-Nrf2 Protein-Protein Interaction. Bioorg. Med. Chem. Lett. 2013 ; 23 (10). 3039-3043
24. Savitsky P., Bray J., Cooper C., et al. High-Throughput Production of Human Proteins for Crystallization: The SGC Experience. J. Struct. Biol. 2010 ; 172 (1). 3-13
25. Punta M., Coggill P. C., Eberhardt R. Y., et al. The Pfam Protein Families Database. Nucleic Acids Res. 2012 ; 40 (Database issue). D290-301
26. Jones D. T.. Protein Secondary Structure Prediction Based on Position-Specific Scoring Matrices. J. Mol. Biol. 1999 ; 292 (2). 195-202
27. Raymond A., Haffner T., Ng N., et al. Gene Design, Cloning and Protein-Expression Methods for High-Value Targets at the Seattle Structural Genomics Center for Infectious Disease. Acta Crystallograph. F. 2011 ; 67 (Pt 9). 992-997
28. Gustafsson C., Govindarajan S., Minshull J.. Codon Bias and Heterologous Protein Expression. Trends Biotechnol. 2004 ; 22 (7). 346-353
29. Ermolaeva M.. Synonymous Codon Usage in Bacteria. Curr. Issues Molec. Biol. 2001 ; 3: 91-97
30. Wu G., Zheng Y., Qureshi I., et al. SGDB: A Database of Synthetic Genes Re-designed for Optimizing Protein Over-expression. Nucleic Acids Res. 2007 ; 35 (Database issue). 9
31. Gustafsson C., Minshull J., Govindarajan S.. Engineering Genes for Predictable Protein Expression. Protein Expression and.... 2012 ; 83 (1). 37-46
32. Cannarozzi G., Cannarrozzi G., Schraudolph N., et al. A Role for Codon Order in Translation Dynamics. Cell. 2010 ; 141 (2). 355-367
33. Goodman D., Church G., Kosuri S.. Causes and Effects of N-Terminal Codon Bias in Bacterial Genes. Science (New York, N.Y.). 2013 ; 342 (6157). 475-479
34. Trotta E.. Selection on Codon Bias in Yeast: A Transcriptional Hypothesis. Nucleic Acids Res. 2013 ; 41 (20). 9382-9395
35. Novoa E., Ribas de Pouplana L.. Speeding with Control: Codon Usage, tRNAs, and Ribosomes. Trends Genet. 2012 ; 28 (11). 574-581
36. Zhang G., Hubalewska M., Ignatova Z.. Transient Ribosomal Attenuation Coordinates Protein Synthesis and Co-translational Folding. Nat. Struct. Molec. Biol. 2009 ; 16 (3). 274-280
37. Saunders R., Deane C. M.. Synonymous Codon Usage Influences the Local Protein Structure Observed. Nucleic Acids Res. 2010 ; 38 (19). 6719-6728
38. Edwards N., Hing Z., Perry A., et al. Characterization of Coding Synonymous and Non-synonymous Variants in ADAMTS13 Using Ex Vivo and In Silico Approaches. PloS One. 2012 ; 7 (6). e38864
39. Xu Y., Ma P., Shah P., et al. Non-optimal Codon Usage Is a Mechanism to Achieve Circadian Clock Conditionality. Nature. 2013 ; 495 (7439). 116-120
40. Zhou M., Guo J., Cha J., et al. Non-optimal Codon Usage Affects Expression, Structure and Function of Clock Protein FRQ. Nature. 2013 ; 495 (7439). 111-115
41. Kimchi-Sarfaty C., Oh J., Kim I.-W., et al. A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science (New York, N.Y.). 2007 ; 315 (5811). 525-528
42. Young C., Britton Z., Robinson A.. Recombinant Protein Expression and Purification: A Comprehensive Review of Affinity Tags and Microbial Applications. Biotechnology J. 2012 ; 7 (5). 620-634
43. Bell M. R., Engleka M. J., Malik A., et al. To Fuse or Not to Fuse: What Is Your Purpose?. Protein Sci. 2013 ; 22 (11). 1466-1477
44. LaVallie E. R., Lu Z., Diblasio-Smith E. A., et al. Thioredoxin as a Fusion Partner for Production of Soluble Recombinant Proteins in Escherichia coli. Methods Enzymol. 2000 ; 326: 322-340
45. Malakhov M. P., Mattern M. R., Malakhova O. A., et al. SUMO Fusions and SUMO-Specific Protease for Efficient Expression and Purification of Proteins. J. Struct. Funct. Genomics. 2004 ; 5 (1-2). 75-86
46. Davis G. D., Elisee C., Newham D. M., et al. New Fusion Protein Systems Designed to Give Soluble Expression in Escherichia coli. Biotechnol. Bioeng. 1999 ; 65 (4). 382-388
47. Gusarov I., Nudler E.. Control of Intrinsic Transcription Termination by N and NusA: The Basic Mechanisms. Cell. 2001 ; 107 (4). 437-449
48. Ahn J.-H., Keum J.-W., Kim D.-M.. Expression Screening of Fusion Partners from an E. coli Genome for Soluble Expression of Recombinant Proteins in a Cell-Free Protein Synthesis System. PloS One. 2011 ; 6 (11). e26875
49. Yansura D. G.. Expression as trpE Fusion. Methods Enzymol. 1990 ; 185: 161-166
50. Athan K., Christopher T. W.. Production, Purification, and Cleavage of Tandem Repeats of Recombinant Peptides. JACS. 1994 ; 116: 4599-4607
51. Hwang P. M., Pan J. S., Sykes B. D.. A PagP Fusion Protein System for the Expression of Intrinsically Disordered Proteins in Escherichia coli. Protein Expr. Purif. 2012 ; 85 (1). 148-151
52. Park T.-J., Kim J.-S., Choi S.-S., et al. Cloning, Expression, Isotope Labeling, Purification, and Characterization of Bovine Antimicrobial Peptide, Lactophoricin in Escherichia coli. Protein Expr. Purif. 2009 ; 65 (1). 23-29
53. Hwang P., Pan J., Sykes B.. Targeted Expression, Purification, and Cleavage of Fusion Proteins from Inclusion Bodies in Escherichia coli. FEBS Lett. 2013 ;:
54. Britton Z. T., Hanle E. I., Robinson A. S.. An Expression and Purification System for the Biosynthesis of Adenosine Receptor Peptides for Biophysical and Structural Characterization. Protein Expr. Purif. 2012 ; 84 (2). 224-235
55. Degorce F., Card A., Soh S., et al. HTRF: A Technology Tailored for Drug Discovery - a Review of Theoretical Aspects and Recent Applications. Curr. Chem. Genom. 2009 ; 3: 22-32
56. Chaga G. S.. Twenty-Five Years of Immobilized Metal Ion Affinity Chromatography: Past, Present and Future. J. Biochem. Biophys. Meth. 2001 ; 49 (1-3). 313-334
57. Lee J., Kim S.-H.. High-Throughput T7 LIC Vector for Introducing C-Terminal Poly-Histidine Tags with Variable Lengths without Extra Sequences. Protein Expr. Purif. 2009 ; 63 (1). 58-61
58. Smith D., Johnson K.. Single-Step Purification of Polypeptides Expressed in Escherichia coli as Fusions with Glutathione S-Transferase. Gene. 1988 ; 67 (1). 31-40
59. di Guan C., Li P., Riggs P., et al. Vectors That Facilitate the Expression and Purification of Foreign Peptides in Escherichia coli by Fusion to Maltose-Binding Protein. Gene. 1988 ; 67 (1). 21-30
60. Einhauer A., Jungbauer A.. The FLAG Peptide, a Versatile Fusion Tag for the Purification of Recombinant Proteins. J. Biochem. Biophys. Meth. 2001 ; 49 (1-3). 455-465
61. Lichty J., Malecki J., Agnew H., et al. Comparison of Affinity Tags for Protein Purification. Protein Expr. Purif. 2005 ; 41 (1). 98-105
62. Schmidt T., Skerra A.. The Random Peptide Library-Assisted Engineering of a C-Terminal Affinity Peptide, Useful for the Detection and Purification of a Functional Ig Fv Fragment. Prot. Engin. 1993 ; 6 (1). 109-122
63. Korndorfer I. P.. Improved Affinity of Engineered Streptavidin for the Strep-Tag II Peptide Is Due to a Fixed Open Conformation of the Lid-Like Loop at the Binding Site. Protein Sci. 2002 ; 11: 883-893
64. Keefe A., Wilson D., Seelig B., et al. One-Step Purification of Recombinant Proteins Using a Nanomolar-Affinity Streptavidin-Binding Peptide, the SBP-Tag. Protein Expr. Purif. 2001 ; 23 (3). 440-446
65. Wu S.-C., Wong S.-L.. Structure-Guided Design of an Engineered Streptavidin with Reusability to Purify Streptavidin-Binding Peptide Tagged Proteins or Biotinylated Proteins. PloS One. 2013 ; 8 (7). e69530
66. Charlton A., Zachariou M.. Tag Removal by Site-Specific Cleavage of Recombinant Fusion Proteins. Meth. Molec. Biol. 2011 ; 681: 349-367
67. Marblestone J., Edavettal S., Lim Y., et al. Comparison of SUMO Fusion Technology with Traditional Gene Fusion Systems: Enhanced Expression and Solubility with SUMO. Protein Sci. 2006 ; 15 (1). 182-189
68. Simpson R., Hammacher A., Smith D., et al. Interleukin-6: Structure-Function Relationships. Protein Sci. 1997 ; 6 (5). 929-955
69. Nausch H., Huckauf J., Koslowski R., et al. Recombinant Production of Human Interleukin 6 in Escherichia coli. PloS One. 2013 ; 8 ( 1 ):
70. de Marco A.. Strategies for Successful Recombinant Expression of Disulfide Bond-Dependent Proteins in Escherichia coli. Microb. Cell Fact. 2009 ; 8: 26
71. Arié J.-P., Miot M., Sassoon N., et al. Formation of Active Inclusion Bodies in the Periplasm of Escherichia coli. Molec. Microbiol. 2006 ; 62 (2). 427-437
72. Martin C., Rojas G., Mitchell J., et al. A Simple Vector System to Improve Performance and Utilisation of Recombinant Antibodies. BMC Biotech. 2006 ; 6: 46
73. Contreras-Gómez A., Sánchez-Mirón A., García-Camacho F., et al. Protein Production Using the Baculovirus-Insect Cell Expression System. Biotechnol. Prog. 2014 ;:
74. Assenberg R., Wan P., Geisse S., et al. Advances in Recombinant Protein Expression for Use in Pharmaceutical Research. Curr. Opin. Struct. Biol. 2013 ; 23 (3). 393-402
75. Kato T., Kajikawa M., Maenaka K., et al. Silkworm Expression System as a Platform Technology in Life Science. Appl. Microbiol. Biotechnol. 2010 ; 85 (3). 459-470
76. Harrison R. L., Jarvis D. L.. Protein N-Glycosylation in the Baculovirus-Insect Cell Expression System and Engineering of Insect Cells to Produce "Mammalianized" Recombinant Glycoproteins. Adv. Virus Res. 2006 ; 68: 159-191
77. Rothan H., Teh S., Haron K., et al. A Comparative Study on the Expression, Purification and Functional Characterization of Human Adiponectin in Pichia pastoris and Escherichia coli. Intl. J. Molec. Sci. 2012 ; 13 (3). 3549-3562
78. Li H., Hui X., Yang S., et al. High Level Expression, Efficient Purification and Bioactivity Assay of Recombinant Human Platelet-Derived Growth Factor AA Dimer (PDGF-AA) from Methylotrophic Yeast. Pichia pastoris. Protein Expr. Purif. 2013 ; 91 (2). 221-227
79. Li J., Lin Y., Zhuang H., et al. Expression, Purification, and Biological Characterization of the Amino-Terminal Fragment of Urokinase in Pichia pastoris. J. Microbiol. Biotech. 2013 ; 23 (9). 1197-1205
80. Krainer F., Dietzsch C., Hajek T., et al. Recombinant Protein Expression in Pichia pastoris Strains with an Engineered Methanol Utilization Pathway. Microb. Cell Fact. 2012 ; 11: 22
81. Diehl B., Hoffmann T. M., Mueller N. C., et al. Novel Yeast Bioassay for High-Throughput Screening of Matrix Metalloproteinase Inhibitors. Appl. Environ. Microbiol. 2011 ; 77: 8573-8577
82. Jäger V., Büssow K., Wagner A., et al. High Level Transient Production of Recombinant Antibodies and Antibody Fusion Proteins in HEK293 Cells. BMC Biotech. 2013 ; 13 (1). 52
83. Meyer S., Lorenz C., Baser B., et al. Multi-Host Expression System for Recombinant Production of Challenging Proteins. PloS One. 2013 ; 8 (7). e68674
84. Chapple S., Crofts A., Shadbolt S., et al. Multiplexed Expression and Screening for Recombinant Protein Production in Mammalian Cells. BMC Biotech. 2006 ; 6: 49
85. Zhao Y., Bishop B., Clay J., et al. Automation of Large Scale Transient Protein Expression in Mammalian Cells. J. Struct. Biol. 2011 ; 175 (2). 209-215
86. Parrill A. L., Baker D. L.. Autotaxin Inhibition: Challenges and Progress toward Novel Anti-Cancer Agents. Anticancer Agents Med. Chem. 2008 ; 8 (8). 917-923
87. Song Y., Dilger E., Bell J., et al. Large Scale Purification and Characterization of Recombinant Human Autotaxin/Lysophospholipase D from Mammalian Cells. BMB Rep. 2010 ; 43 (8). 541-546
88. Nishimasu H., Okudaira S., Hama K., et al. Crystal Structure of Autotaxin and Insight into GPCR Activation by Lipid Mediators. Nat. Struct. Molec. Biol. 2011 ; 18 (2). 205-212
89. Gierse J., Thorarensen A., Beltey K., et al. A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation. J. Pharm. Exper. Therap. 2010 ; 334 (1). 310-317
90. Niimi T.. Recombinant Protein Production in the Eukaryotic Protozoan Parasite Leishmania tarentolae: A Review. Meth. Molec. Biol. 2012 ; 824: 307-315
91. Breitling R., Klingner S., Callewaert N., et al. Non-Pathogenic Trypanosomatid Protozoa as a Platform for Protein Research and Production. Protein Expr. Purif. 2002 ; 25 (2). 209-218
92. Phan H. P., Sugino M., Niimi T.. The Production of Recombinant Human Laminin-332 in a Leishmania tarentolae Expression System. Protein Expr. Purif. 2009 ; 68 (1). 79-84
93. Gazdag E., Cirstea I., Breitling R., et al. Purification and Crystallization of Human Cu/Zn Superoxide Dismutase Recombinantly Produced in the Protozoan. Leishmania tarentolae. Acta Crystallograph. F. 2010 ; 66 (Pt. 8). 871-877
94. Baechlein C., Meemken D., Pezzoni G., et al. Expression of a Truncated Hepatitis E Virus Capsid Protein in the Protozoan Organism Leishmania tarentolae and Its Application in a Serological Assay. J. Virol. Meth. 2013 ; 193 (1). 238-243
95. Murray C. J., Baliga R.. Cell-Free Translation of Peptides and Proteins: From High Throughput Screening to Clinical Production. Curr. Opin. Chem. Biol. 2013 ; 17 (3). 420-426
96. Brödel A., Sonnabend A., Kubick S.. Cell-Free Protein Expression Based on Extracts from CHO Cells. Biotechnol. Bioengin. 2013 ; 111: 25-36
97. Garland S. L.. Are GPCRs Still a Source of New Targets?. J. Biomol. Screen. 2013 ; 18 (9). 947-966
98. Hopkins A. L., Groom C. R.. The Druggable Genome. Nat. Rev. Drug Discov. 2002 ; 1 (9). 727-730
99. Bernaudat F., Frelet-Barrand A., Pochon N., et al. Heterologous Expression of Membrane Proteins: Choosing the Appropriate Host. PloS One. 2011 ; 6 ( 12 ):
100. Silvius J. R.. Solubilization and Functional Reconstitution of Biomembrane Components. Ann. Rev. Biophys. Biomol. Struct. 1992 ; 21: 323-348
101. le Maire M., Champeil P., Moller J. V.. Interaction of Membrane Proteins and Opioids with Solubilizing Detergents. Biochim. Biophys. Acta. 2000 ; 1508 (1-2). 86-111
102. Zhou Y., Bowie J. U.. Building a Thermostable Membrane Protein. J. Biol. Chem. 2000 ; 275 (10). 6975-6979
103. Sarver N., Black R. J., Bridges S., et al. Frontiers in HIV-1 Therapy: Fourth Conference of the NIAID National Cooperative Drug Discovery Groups-HIV. AIDS Res. Hum. Retroviruses. 1992 ; 8 (5). 659-667
104. Witvrouw M., Pauwels R., Vandamme A. M., et al. Cell Type-Specific Anti-Human Immunodeficiency Virus Type 1 Activity of the Transactivation Inhibitor Ro5-3335. Antimicrob. Agents Chemother. 1992 ; 36 (12). 2628-2633
105. Hendricson A., Matchett M., Ferrante M., et al. Design of an Automated Enhanced-Throughput Platform for Functional Characterization of Positive Allosteric Modulator-Induced Leftward Shifts in Apparent Agonist Potency in Vitro. J. Lab. Autom. 2012 ; 17 (2). 104-115
106. Noblin D. J., Bertekap R. L., Burford N. T., et al. Development of a High-Throughput Calcium Flux Assay for Identification of All Ligand Types including Positive, Negative, and Silent Allosteric Modulators for G Protein-Coupled Receptors. Assay Drug Dev. Technol. 2012 ; 10 (5). 457-467
107. Claing A., Laporte S., Caron M., et al. Endocytosis of G Protein-Coupled Receptors: Roles of G Protein-Coupled Receptor Kinases and Beta-Arrestin Proteins. Prog. Neurobiol. 2002 ; 66 (2). 61-79
108. Dores M. R., Trejo J.. Ubiquitination of G Protein-Coupled Receptors: Functional Implications and Drug Discovery. Molec. Pharmacol. 2012 ; 82 (4). 563-570
109. Morello J. P., Bouvier M.. Palmitoylation: A Post-Translational Modification That Regulates Signalling from G-Protein Coupled Receptors. Biochem. Cell Biol. 1996 ; 74 (4). 449-457
110. Wheatley M., Hawtin S. R.. Glycosylation of G-Protein-Coupled Receptors for Hormones Central to Normal Reproductive Functioning: Its Occurrence and Role. Hum. Reprod. Update. 1999 ; 5 (4). 356-364
111. Klenk H.. Post-Translational Modifications in Insect Cells. Cytotechnology. 1996 ; 20 (1-3). 139-144
112. Bjorklof K., Lundstrom K., Abuin L., et al. Co- and Posttranslational Modification of the Alpha(1B)-Adrenergic Receptor: Effects on Receptor Expression and Function. Biochemistry. 2002 ; 41 (13). 4281-4291
113. Hanson M. A., Brooun A., Baker K. A., et al. Profiling of Membrane Protein Variants in a Baculovirus System by Coupling Cell-Surface Detection with Small-Scale Parallel Expression. Protein Expr. Purif. 2007 ; 56 (1). 85-92
114. Aloia A. L., Glatz R. V., McMurchie E. J., et al. GPCR Expression Using Baculovirus-Infected Sf9 Cells. Meth. Molec. Biol. 2009 ; 552: 115-129
115. McCusker E. C., Bane S. E., O'Malley M. A., et al. Heterologous GPCR Expression: A Bottleneck to Obtaining Crystal Structures. Biotechnol. Prog. 2007 ; 23 (3). 540-547
116. Asada H., Uemura T., Yurugi-Kobayashi T., et al. Evaluation of the Pichia pastoris Expression System for the Production of GPCRs for Structural Analysis. Microb. Cell Fact. 2011 ; 10: 24
117. Davenport E. A., Nuthulaganti P., Ames R. S.. BacMam: Versatile Gene Delivery Technology for GPCR Assays. Methods Mol. Biol. 2009 ; 552: 199-211
118. Kost T. A., Condreay J. P., Ames R. S., et al. Implementation of BacMam Virus Gene Delivery Technology in a Drug Discovery Setting. Drug Discov. Today. 2007 ; 12 (9-10). 396-403
119. Scott D., Kummer L., Tremmel D., et al. Stabilizing Membrane Proteins through Protein Engineering. Curr. Opin. Chem. Biol. 2013 ; 17 (3). 427-435
120. Serrano-Vega M., Tate C.. Transferability of Thermostabilizing Mutations between Beta-Adrenergic Receptors. Molec. Memb. Biol. 2009 ; 26 (8). 385-396
121. Stevens R. C., Cherezov V., Katritch V., et al. The GPCR Network: A Large-Scale Collaboration to Determine Human GPCR Structure and Function. Nat. Rev. Drug Discov. 2013 ; 12 (1). 25-34
122. Siu F. Y., He M., de Graaf C., et al. Structure of the Human Glucagon Class B G-Protein-Coupled Receptor. Nature. 2013 ; 499 (7459). 444-449
123. Koth C. M., Murray J. M., Mukund S., et al. Molecular Basis for Negative Regulation of the Glucagon Receptor. Proc. Natl. Acad. Sci. USA. 2012 ; 109 (36). 14393-14398
124. Rasmussen S. G., Choi H. J., Fung J. J., et al. Structure of a Nanobody-Stabilized Active State of the Beta(2) Adrenoceptor. Nature. 2011 ; 469 (7329). 175-180
125. Rasmussen S. G., DeVree B. T., Zou Y., et al. Crystal Structure of the Beta2 Adrenergic Receptor-Gs Protein Complex. Nature. 2011 ; 477 (7366). 549-555
126. Steyaert J., Kobilka B. K.. Nanobody Stabilization of G Protein-Coupled Receptor Conformational States. Curr. Opin. Struct. Biol. 2011 ; 21 (4). 567-572
127. Muyldermans S., Baral T. N., Retamozzo V. C., et al. Camelid Immunoglobulins and Nanobody Technology. Vet. Immunol. Immunopathol. 2009 ; 128 (1-3). 178-183
128. Nath A., Atkins W. M., Sligar S. G.. Applications of Phospholipid Bilayer Nanodiscs in the Study of Membranes and Membrane Proteins. Biochemistry. 2007 ; 46 (8). 2059-2069
129. Denisov I. G., Grinkova Y. V., Lazarides A. A., et al. Directed Self-Assembly of Monodisperse Phospholipid Bilayer Nanodiscs with Controlled Size. J. Am. Chem. Soc. 2004 ; 126 (11). 3477-3487
130. Timothy H. B., Yelena V. G., Stephen G. S.. Self-Assembly of Discoidal Phospholipid Bilayer Nanoparticles with Membrane Scaffold Proteins. Nano. Lett. 2002 ; 2: 853-856
131. Osenkowski P., Ye W., Wang R., et al. Direct and Potent Regulation of Gamma-Secretase by Its Lipid Microenvironment. J. Biol. Chem. 2008 ; 283 (33). 22529-22540
132. Service R. F.. Structural Genomics. Tapping DNA for Structures Produces a Trickle. Science. 2002 ; 298 (5595). 948-950